Shares in EKF Diagnostics, the AIM-listed in-vitro diagnostics company, fell on Wednesday despite the group appearing to beat analysts' forecasts in 2011.
Revenues more than tripled from £6.5m to £21.7m, helped by 64% growth in EKF Germany and 144% in its Quotient division.
While margins improved from 45% to 48%, the loss before tax widened from £2.1m to £2.4m due to the acquisition costs associated with the purchase of Stanbio in June.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) rose to £1.6m from £.10m.
Collins Stewart, EKF's house broker, upgraded its 2012 adjusted EBITDA forecasts by 6%. The broker has a target price of 43p for the shares.
"We expect solid trading in 2012 to be supported by updates on new product
launches, product in-licensing and distribution agreements providing positive
momentum. A distribution deal for QuoLab, which we expect to be signed in
2012, would likely result in a significant positive change to estimates," the broker said.
Peel Hunt, meanwhile, noted that the figures were in line with twice upgraded forecasts.
"Sales more than tripled to £21.7m, driven by a six-month contribution from Stanbio in the US, growth in haemoglobin cartridge sales and capital sales to developing markets (Peru, Mexico)," Peel Hunt's Dr Paul Cuddon said."Net cash of £5.3m is ahead of our expectations," Dr Cuddon added.
"EKF Diagnostics has assembled a strong direct sales presence and distributor network, with a portfolio of products the key to driving significant operating leverage," Dr Cuddon opined.
The shares trade on an undemanding two times enterprise value/sales, underscoring Peel Hunt's "buy" recommendation and 35p target price.
Meanwhile, the company stressed that "it is important that our 2011 result is seen in context and that none of us get carried away with a heightened sense of expectation. 2012 remains a transitional year."
Shares were down 3.14% at 27p.
BC/jh
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
-
What does Rachel Reeves’s plan for growth mean for UK investors?Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
